COMMUNIQUÉS West-GlobeNewswire

-
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
09/04/2025 -
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
09/04/2025 -
Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors
09/04/2025 -
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
09/04/2025 -
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
09/04/2025 -
Coave Therapeutics to Attend Upcoming Conferences
09/04/2025 -
Emirati Women Chapter Onboards Second Cohort of 62 Participants
09/04/2025 -
Barbara Weber, M.D., Elected to ITM Supervisory Board
09/04/2025 -
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
09/04/2025 -
SBC Medical to Present at the Emerging Growth Conference on April 17, 2025
09/04/2025 -
ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO
09/04/2025 -
Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer
09/04/2025 -
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
09/04/2025 -
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
09/04/2025 -
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
09/04/2025 -
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
09/04/2025 -
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
09/04/2025 -
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
09/04/2025 -
Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors
09/04/2025
Pages